150 related articles for article (PubMed ID: 26048444)
1. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
2. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines.
Yamazaki H; Takagi S; Hoshino Y; Hosoya K; Okumura M
PLoS One; 2013; 8(11):e79810. PubMed ID: 24260303
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
6. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
7. Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Elliott J
Aust Vet J; 2018 Dec; 96(12):502-507. PubMed ID: 30478839
[TBL] [Abstract][Full Text] [Related]
8. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin.
Miyamoto R; Tani H; Ikeda T; Saima H; Tamura K; Bonkobara M
Res Vet Sci; 2021 Mar; 135():412-415. PubMed ID: 33160684
[TBL] [Abstract][Full Text] [Related]
9. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
10. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
11. Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Miyamoto R; Kurita S; Tani H; Ikeda T; Ishizaka M; Saima H; Kobayashi M; Tamura K; Bonkobara M
Vet J; 2018 Oct; 240():31-36. PubMed ID: 30268330
[TBL] [Abstract][Full Text] [Related]
12. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
13. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
[TBL] [Abstract][Full Text] [Related]
14. Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.
Lai PC; Chen SH; Yang SH; Cheng CC; Chiu TH; Huang YT
Pediatr Neonatol; 2012 Jun; 53(3):199-204. PubMed ID: 22770110
[TBL] [Abstract][Full Text] [Related]
15. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
16. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
18. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
19. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
